|[August 30, 2013]
New Number of Shares and Votes In BioInvent International AB (publ)
LUND, Sweden --(Business Wire)--
BioInvent International AB (OMXS: BINV)
BioInvent International AB (publ) (OMXS:BINV) today announced that the
company's total number of shares as per 30 August 2013 amounts to
85,014,649 shares, corresponding to an equal number of votes. The
increase in the number of shares and votes results from the rights issue
of 10,560,826 shares with preferential right for the company's
shareholders that was announced on 19 June 2013 and the additional
528,041 shares that were issued in a so-called over-allotment option in
connection to the rights issue.
To the editors:
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV),
is a research-based pharmaceutical company focused on discovery and
development of innovative antibody-based drugs against cancer. The
Company's pipeline currently includes three product candidates for the
treatment of cancer.
The Company's competitive position is underpinned by n-CoDeR®,
a proprietary antibody development platform. The scope and strength of
this platform is also used to develop antibody-based drugs in
collaboration with partners who finance the development of the new drug,
and provide BioInvent the right to milestone payments and royalties on
sales. These partners include Bayer HealthCare, Daiichi Sankyo,
Mitsubishi (News - Alert) Tanabe and Servier. More information is available at www.bioinvent.com.
Information disclosed in this press release is provided herein pursuant
to the Swedish Financial Instruments Trading Act. The information was
submitted for publication at 8.45 a.m. CET, on 30 August 2013.
[ Back To Technology News's Homepage ]